Can Theileria equi be eliminated from carrier horses?

The research article explores the potential for Theileria equi, a parasite causing Equine piroplasmosis (EP) in horses, to be eliminated using multiple high-dose imidacarb dipropionate treatments. The researchers find that this treatment is effective in most cases, but efficacy may be influenced by strain and co-infection with other parasites, necessitating further study.

Study Overview

• This study addresses a gap in knowledge about whether T. equi, a parasitic infection in horses, can be successfully eliminated using high-dose imidocarb dipropionate treatments.
• Although the researchers held encouraging results, with five out of six experimentally infected horses responding positively to the treatment, the research also acknowledges that one of the horses remained infected after treatment, hinting at a possible strain or host-dependency of the treatment’s efficacy.

Comparison to Prior Research

• Two earlier studies contradict these findings, showing no effective use of the treatment against a European T. equi strain or for horses simultaneously infected with B. caballi and T. equi, suggesting the successful elimination of the parasite might be strain-dependent.
• The researchers also note an additional recent study that seems to confirm the effectiveness of their treatment method, but the study neglected to identify the strains of T. equi, leaving the possibility open that the method’s success could be strain-dependent.

Practical Application and Implications

• The researchers suggest that even though high-dose imidocarb dipropionate treatment for T. equi can be successful, proper follow-up testing is necessary for ensuring a disease-free condition.
• They also highlight the need for further research into how individual host factors and co-infections with other parasites might impact treatment effectiveness.
• Furthermore, they stress the importance of ongoing monitoring of competent tick vectors, which are the primary carriers of EP, as crucial for assessing any risk associated with this disease.